These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 32301833)

  • 21. Long-term outcome of tumor necrosis factor alpha antagonist's treatment in pediatric Crohn's disease.
    Assa A; Hartman C; Weiss B; Broide E; Rosenbach Y; Zevit N; Bujanover Y; Shamir R
    J Crohns Colitis; 2013 Jun; 7(5):369-76. PubMed ID: 22483567
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The VICM biomarker is released from activated macrophages and inhibited by anti-GM-CSFRα-mAb treatment in rheumatoid arthritis patients.
    Mortensen JH; Guo X; De Los Reyes M; Dziegiel MH; Karsdal MA; Bay-Jensen AC; White WI
    Clin Exp Rheumatol; 2019; 37(1):73-80. PubMed ID: 30418117
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of tumor necrosis factor-α antagonists on oxidative stress in patients with Crohn's disease.
    Yamamoto K; Chiba T; Matsumoto T
    World J Gastroenterol; 2015 Sep; 21(35):10208-14. PubMed ID: 26401086
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Therapeutic Drug Monitoring Increases Drug Retention of Anti-Tumor Necrosis Factor Alpha Agents in Pediatric Patients With Crohn's Disease.
    Gofin Y; Matar M; Shamir R; Assa A
    Inflamm Bowel Dis; 2020 Jul; 26(8):1276-1282. PubMed ID: 31634402
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Long-term follow-up of inflammatory bowel disease patients receiving anti-tumor necrosis factor-alpha therapy].
    Bacsur P; Skribanek S; Milassin Á; Farkas K; Bor R; Fábián A; Rutka M; Bálint A; Szántó KJ; Tóth T; Nagy F; Szepes Z; Boda K; Molnár T
    Orv Hetil; 2020 Nov; 161(47):1989-1994. PubMed ID: 33226355
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease.
    Behm BW; Bickston SJ
    Cochrane Database Syst Rev; 2008 Jan; (1):CD006893. PubMed ID: 18254120
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Magnetic resonance enterographic predictors of one-year outcome in ileal and ileocolonic Crohn's disease treated with anti-tumor necrosis factor antibodies.
    Eder P; Michalak M; Katulska K; Lykowska-Szuber L; Krela-Kazmierczak I; Stawczyk-Eder K; Klimczak K; Szymczak A; Linke K
    Sci Rep; 2015 May; 5():10223. PubMed ID: 25993615
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Expression of Circulating let-7e and miR-126 May Predict Clinical Remission in Patients With Crohn's Disease Treated With Anti-TNF-α Biologics.
    Guglielmi G; Crucitta S; Bertani L; Ruglioni M; Baiano Svizzero G; Ceccarelli L; Del Re M; Danesi R; Costa F; Fogli S
    Inflamm Bowel Dis; 2024 Mar; 30(3):441-446. PubMed ID: 37696681
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Circulating citrullinated vimentin fragments reflect disease burden in ankylosing spondylitis and have prognostic capacity for radiographic progression.
    Bay-Jensen AC; Karsdal MA; Vassiliadis E; Wichuk S; Marcher-Mikkelsen K; Lories R; Christiansen C; Maksymowych WP
    Arthritis Rheum; 2013 Apr; 65(4):972-80. PubMed ID: 23280360
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Actual Anti-TNF Trough Levels Relate to Serum IL-10 in Drug-Responding Patients With Crohn's Disease.
    Zapater P; Almenara S; Gutiérrez A; Sempere L; García M; Laveda R; Martínez A; Scharl M; Cameo JI; Linares R; González-Navajas JM; Wiest R; Rogler G; Francés R
    Inflamm Bowel Dis; 2019 Jul; 25(8):1357-1366. PubMed ID: 30776076
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Optimized thiopurine therapy before withdrawal of anti-tumour necrosis factor-α in patients with Crohn's disease.
    Bohn Thomsen S; Kiszka-Kanowitz M; Theede K; Gluud LL; Mertz Nielsen A
    Eur J Gastroenterol Hepatol; 2018 Oct; 30(10):1155-1158. PubMed ID: 29975242
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Early Initiation of Tumor Necrosis Factor Antagonist-Based Therapy for Patients With Crohn's Disease Reduces Costs Compared With Late Initiation.
    Beilman CL; Kirwin E; Ma C; McCabe C; Fedorak RN; Halloran B
    Clin Gastroenterol Hepatol; 2019 Jul; 17(8):1515-1524.e4. PubMed ID: 30056180
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Citrullinated vimentin and biglycan protein fingerprints as candidate serological biomarkers for disease activity in systemic sclerosis: a pilot study.
    Siebuhr AS; Juhl P; Bay-Jensen AC; Karsdal MA; Franchimont N; Chavez JC
    Biomarkers; 2019 May; 24(3):249-254. PubMed ID: 30457356
    [No Abstract]   [Full Text] [Related]  

  • 34. Elective switching from infliximab to adalimumab in stable Crohn's disease.
    Hoentjen F; Haarhuis BJ; Drenth JP; de Jong DJ
    Inflamm Bowel Dis; 2013; 19(4):761-6. PubMed ID: 23446337
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Anti-TNF therapy in treatment of luminal Crohn's disease].
    Marko B; Prka L
    Acta Med Croatica; 2013 Apr; 67(2):179-89. PubMed ID: 24471301
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Growth and Adult Height in Patients with Crohn's Disease Treated with Anti-Tumor Necrosis Factor α Antibodies.
    Bamberger S; Martinez Vinson C; Mohamed D; Viala J; Carel JC; Hugot JP; Simon D
    PLoS One; 2016; 11(9):e0163126. PubMed ID: 27636201
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term outcomes of patients with Crohn's disease who received infliximab or adalimumab as the first-line biologics.
    Inokuchi T; Takahashi S; Hiraoka S; Toyokawa T; Takagi S; Takemoto K; Miyaike J; Fujimoto T; Higashi R; Morito Y; Nawa T; Suzuki S; Nishimura M; Inoue M; Kato J; Okada H
    J Gastroenterol Hepatol; 2019 Aug; 34(8):1329-1336. PubMed ID: 30724387
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of infliximab with adalimumab in 827 biologic-naïve patients with Crohn's disease: a population-based Danish cohort study.
    Singh S; Andersen NN; Andersson M; Loftus EV; Jess T
    Aliment Pharmacol Ther; 2018 Mar; 47(5):596-604. PubMed ID: 29239001
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mucosal IL13RA2 expression predicts nonresponse to anti-TNF therapy in Crohn's disease.
    Verstockt B; Verstockt S; Creyns B; Tops S; Van Assche G; Gils A; Ceuppens JL; Vermeire S; Ferrante M; Breynaert C
    Aliment Pharmacol Ther; 2019 Mar; 49(5):572-581. PubMed ID: 30663072
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Circulating levels of citrullinated and MMP-degraded vimentin (VICM) in liver fibrosis related pathology.
    Vassiliadis E; Oliveira CP; Alvares-da-Silva MR; Zhang C; Carrilho FJ; Stefano JT; Rabelo F; Pereira L; Kappel CR; Henriksen K; Veidal SS; Vainer B; Duffin KL; Christiansen C; Leeming DJ; Karsdal M
    Am J Transl Res; 2012; 4(4):403-14. PubMed ID: 23145208
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.